Compare JAZZ & JHX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JAZZ | JHX |
|---|---|---|
| Founded | 2003 | 1888 |
| Country | Ireland | Ireland |
| Employees | N/A | 5860 |
| Industry | Biotechnology: Pharmaceutical Preparations | Building Materials |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4B | 11.4B |
| IPO Year | 2007 | N/A |
| Metric | JAZZ | JHX |
|---|---|---|
| Price | $180.50 | $20.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 9 |
| Target Price | ★ $215.92 | $28.50 |
| AVG Volume (30 Days) | 966.4K | ★ 4.8M |
| Earning Date | 05-05-2026 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,618,693,000.00 | N/A |
| Revenue This Year | $6.17 | $25.60 |
| Revenue Next Year | $7.66 | $15.24 |
| P/E Ratio | ★ N/A | $122.05 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $95.49 | $16.46 |
| 52 Week High | $198.00 | $29.83 |
| Indicator | JAZZ | JHX |
|---|---|---|
| Relative Strength Index (RSI) | 52.38 | 33.66 |
| Support Level | $176.67 | $18.98 |
| Resistance Level | $182.99 | $20.95 |
| Average True Range (ATR) | 4.97 | 0.66 |
| MACD | -1.09 | -0.30 |
| Stochastic Oscillator | 25.88 | 18.16 |
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
James Hardie is a manufacturer of fiber cement-based building products, selling primarily to the residential construction industry. North America is the primary geography, generating about 80% of group earnings. Here, it is the largest manufacturer of fiber cement, which is mainly used for exterior siding on houses. Following the Azek acquisition in 2025, it also produces wooden composite decking materials, siding trims, and accessories for outdoor areas including stair and deck railing. Businesses in Australia, New Zealand, and Europe, make up the rest of earnings.